Dr. Vinod Parameswaran
Claim this profileAvera Cancer Institute
Studies Lymphoma
Studies B-Cell Lymphoma
6 reported clinical trials
16 drugs studied
Area of expertise
1Lymphoma
CCND1 positive
t(11;14) positive
2B-Cell Lymphoma
Affiliated Hospitals
Clinical Trials Vinod Parameswaran is currently running
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
More about Vinod Parameswaran
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Vinod Parameswaran has experience with
- Lenalidomide
- Daratumumab/rHuPH20
- Ibrutinib
- Autologous Hematopoietic Stem Cell Transplantation
- Autologous Bone Marrow Transplantation
- CTL019
Breakdown of trials Vinod Parameswaran has run
Lymphoma
B-Cell Lymphoma
Multiple Myeloma
Plasma Cell Neoplasms
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Vinod Parameswaran specialize in?
Vinod Parameswaran focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Vinod Parameswaran currently recruiting for clinical trials?
Yes, Vinod Parameswaran is currently recruiting for 2 clinical trials in Sioux Falls South Dakota. If you're interested in participating, you should apply.
Are there any treatments that Vinod Parameswaran has studied deeply?
Yes, Vinod Parameswaran has studied treatments such as Lenalidomide, Daratumumab/rHuPH20, Ibrutinib.
What is the best way to schedule an appointment with Vinod Parameswaran?
Apply for one of the trials that Vinod Parameswaran is conducting.
What is the office address of Vinod Parameswaran?
The office of Vinod Parameswaran is located at: Avera Cancer Institute, Sioux Falls, South Dakota 57105 United States. This is the address for their practice at the Avera Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.